Navigation Links
ASTRO president speaks on prostate cancer at MEDCAC meeting
Date:4/21/2010

ASTRO President Anthony Zietman, M.D., spoke before the Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) meeting today on radiation therapy for treatment of localized prostate cancer. MEDCAC provides advice and recommendations to the Centers for Medicare and Medicaid Services for what is covered by Medicare and Medicaid, based on scientific evidence. Today's meeting focused on the risks, benefits and outcomes of radiation therapy treatments for localized prostate cancer as compared with watchful waiting.

In his remarks, Dr. Zietman, an expert in radiation therapy treatments for prostate cancer from Massachusetts General Hospital and Harvard University in Boston, provided data on how successful radiation therapy techniques, including external beam radiation therapy and brachytherapy, are at treating prostate cancer without significant side effects. He acknowledged that it is possible some men are receiving treatments for prostate cancer that would have done well without treatment through watchful waiting or active surveillance. However, doctors currently have little way to tell if a man's prostate cancer will progress to be life-threatening or if it will remain somewhat asymptomatic.

With respect to stereotactic body radiation therapy (SBRT), Dr. Zietman said that the treatment, which pinpoints high doses of radiation to the prostate over a few days instead of several weeks, shows promise as a non-invasive way to cure prostate cancer. However, he cautioned that SBRT needed further study in clinical trials to fully capture survival and quality of life measures.

"Prostate cancer is the number one cancer diagnosed in men. I applaud MEDCAC for studying this important issue and appreciate the opportunity to participate in the forum," Dr. Zietman said.


'/>"/>

Contact: Beth Bukata
bethb@astro.org
703-839-7332
American Society for Radiation Oncology
Source:Eurekalert

Page: 1

Related medicine news :

1. A new endoscopic technique for gastrointestinal perforations: the over-the-scope-clip
2. Astrogenetix Narrows in on MRSA Virulence Onboard Discovery
3. Santa Monica Jury Rejects Claims of Catastrophic Brain Injury From Exposure to Mold; Plaintiff Faces Motions for Attorney Fees and Costs
4. ASTRO publishes supplement on protecting cancer patients by reducing radiation doses, side effects
5. ASTRO awards 17 Advocacy Day travel grants
6. ReportsandReports : The Gastrointestinal Market Outlook to 2014: Market Dynamics, Competitive Landscape, Emerging Therapies
7. Senate Committee Advances Disastrous Idaho Health Freedom Act
8. ASTRO, ACR issue IGRT, SBRT guidelines
9. Does Glutathione-S-transferase associate with gastrointestinal cancer in Korean population?
10. Astronaut Balancing Act: Training to Help Explorers Adapt to a Return to Gravity
11. 5,000 deaths: A catastrophic, regrettable decision in Belgium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... ... Immunotherapy has emerged as one of the most promising options for the ... next revolution in our fight against this complex disease. One of the most effective ... such as PD-1 and PD-L1 inhibitors. , While a few single analyte immunohistochemistry tests ...
(Date:3/29/2017)... PA (PRWEB) , ... March 29, 2017 , ... The ... W’80, WG’81, and Julie Taffet Moelis, W’81, have made a $10 million gift to ... deferred admission opportunity that will provide a pathway to a Wharton MBA for highly-qualified ...
(Date:3/28/2017)... , ... March 28, 2017 , ... Tuesday, March 28, ... American public to take the Diabetes Risk Test to find out if they are ... Angeles World Airports will light up the evening sky by programming the LAX pylons ...
(Date:3/28/2017)... ... 28, 2017 , ... Resoundant, Inc., the developer of ... Healthineers annual customer education symposium, a world-class learning conference that offers educational content ... - 31, 2017 at the Atlanta Marriott Marquis in Atlanta, Georgia. , Innovations ...
(Date:3/28/2017)... Seattle, WA (PRWEB) , ... March 28, 2017 ... ... reach a 22% share of all holidays (IBT World Travel Trends Report). As ... physically challenging, include a range in temperatures, and prolonged sun exposure. In response, ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 2017 Neurim Pharmaceuticals ("Neurim") and ... exclusive marketing rights for Neurim,s new Rx PedPRM in ... ... sleep disorders in children with Autism Spectrum Disorders (ASD) and neurogenetic ... for children. The collaboration with Exeltis will help increase ...
(Date:3/29/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The global patient safety and risk management software ... geography. Patient safety has become a priority for ... developed significantly in the last decade and is currently on the ...
(Date:3/28/2017)... Md. , March 28, 2017 ... Dupixent (dupilumab) injection to treat adults with moderate-to-severe ... whose eczema is not controlled adequately by topical ... not advisable. Dupixent can be used with or ... Dupixent demonstrates our commitment to approving new and ...
Breaking Medicine Technology: